U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. BioModeling Solutions, Inc. - 540821 - 01/31/2023
  1. Warning Letters

CLOSEOUT LETTER

BioModeling Solutions, Inc. MARCS-CMS 540821 —

Delivery Method:
VIA Electronic Mail
Product:
Medical Devices

Recipient:
Recipient Name
Kirk Huntsman
Recipient Title
CEO
BioModeling Solutions, Inc.
Vivos Therapeutics, Inc.

7921 Southpark Plaza, Ste. 210
Littleton, CO 80120
United States

kirk@vivoslife.com
Issuing Office:
Los Angeles District Office

United States


Dear Mr. Huntsman,

The Food and Drug Administration has completed an evaluation of your corrective actions in response to Warning Letter #540821-18 dated 1/12/2018. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Jessica Mu
Compliance Branch Director
Office of Medical Devices and Radiological Health Operations
Division 3/West


Cc: Kim Griffith, Director of Compliance, kgriffith@vivoslife.com / Marc Sanchez, Counsel, msanchez@fdaatty.com

 
Back to Top